<DOC>
	<DOCNO>NCT02801565</DOCNO>
	<brief_summary>Observe validity Recombinant Human Growth Hormone Injection assist IVF-ET ( vitro fertilization embryo transfer ) treatment PCOS ( polycystic ovary syndrome ) patient .</brief_summary>
	<brief_title>Clinical Observation Recombinant Human Growth Hormone Injection Assisted IVF-ET Treatment PCOS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Age 25 35 year old , married female infertile . BMI≥25kg/m2 . Diagnosed PCOS . No obvious chronic organic disease , liver , kidney , heart , lung , thyroid , adrenal disease . Subjects take part clinical trial study within 3 month . The subject sign inform consent form . BMI＜25kg/m2 . Hyperprolactinemia congenital adrenal cortical hyperplasia . Diabetes , thyroid function hyperthyroidism , thyroid dysfunction , cushing 's syndrome . Pelvic peritoneal tumor tumor secrete hyperandrogenism . Severe acute chronic liver kidney disease , liver cirrhosis , acute chronic renal failure , hepatitis B virus activity . Liver kidney dysfunction , AST/ALT 2.5 time higher normal limit , serum creatinine 2 time higher normal level . Diseases affect outcome IVF pregnancy , eg , hydrosalpinx , hysteromyoma＞4 cm , adenomyosis , endometriosis , endometrial cyst ovary , unilateral ovary , tuberculosis reproductive system . Allergic E. coli . expression product excipients . Being involve drug clinical researcher . The researcher consider suitable group .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>